Related Experiment Videos
Methodological problems of clinical trials in multi-infarct dementia
1Institute of Neurology, University of Genoa, Italy.
Neuroepidemiology
|January 1, 1990
Summary
Diagnostic uncertainty in Myocardial Infarction with Delirium (MID) impacts clinical trials. Histopathological evidence is crucial for accurate MID diagnosis, affecting study design and patient numbers.
Area of Science:
- Cardiology
- Neurology
- Pathology
Background:
- Myocardial Infarction with Delirium (MID) diagnosis is challenging, with definitive diagnosis requiring histopathological evidence in approximately 30% of cases.
- Diagnostic uncertainty in MID significantly complicates the design and execution of therapeutic clinical trials.
Purpose of the Study:
- To highlight the impact of diagnostic inaccuracy in Myocardial Infarction with Delirium (MID) on therapeutic trial methodology.
- To outline key considerations for therapeutic trials involving patients with potentially uncertain MID diagnoses.
Main Methods:
- Review of diagnostic criteria for Myocardial Infarction with Delirium (MID).
- Analysis of the implications of diagnostic uncertainty on clinical trial parameters.
Main Results:
- Imperfect diagnosis in MID cases decreases the probability of achieving statistically significant results in therapeutic trials.
- Diagnostic inaccuracy necessitates an increase in the number of subjects required for a study.
Conclusions:
- Accurate histopathological diagnosis is essential for reliable Myocardial Infarction with Delirium (MID) assessment.
- Addressing diagnostic challenges is critical for optimizing the design and efficiency of MID therapeutic trials.